Davis Rea LTD. decreased its holdings in Danaher Corporation (NYSE:DHR – Free Report) by 0.7% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 15,108 shares of the conglomerate’s stock after selling 100 shares during the period. Davis Rea LTD.’s holdings in Danaher were worth $2,989,000 as of its most recent SEC filing.
A number of other institutional investors also recently made changes to their positions in DHR. Nuveen LLC purchased a new stake in shares of Danaher in the 1st quarter valued at $833,941,000. Invesco Ltd. boosted its position in Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after buying an additional 1,450,703 shares during the period. Baird Financial Group Inc. boosted its position in Danaher by 290.6% during the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock valued at $295,550,000 after buying an additional 1,072,617 shares during the period. Generation Investment Management LLP boosted its position in Danaher by 33.2% during the 1st quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate’s stock valued at $651,515,000 after buying an additional 791,662 shares during the period. Finally, Parnassus Investments LLC boosted its position in Danaher by 23.3% during the 1st quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock valued at $784,745,000 after buying an additional 722,636 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.
Danaher Trading Down 1.0%
NYSE:DHR opened at $202.53 on Friday. The company has a 50-day moving average price of $200.66 and a 200-day moving average price of $197.25. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.41. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The stock has a market cap of $145.02 billion, a price-to-earnings ratio of 43.09, a P/E/G ratio of 2.91 and a beta of 0.77.
Danaher Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is presently 27.23%.
Analyst Ratings Changes
DHR has been the subject of several analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Danaher in a research report on Wednesday. Bank of America dropped their price target on shares of Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a research report on Monday, September 22nd. Barclays reissued an “overweight” rating and set a $225.00 price target (up previously from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Evercore ISI increased their price target on shares of Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, Robert W. Baird increased their price target on shares of Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a research report on Friday, July 18th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $244.60.
Insider Activity
In related news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.10% of the stock is currently owned by insiders.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- How to start investing in penny stocks
- 3 Heavily Shorted Stocks That Could Pop on Rate Cuts
- Differences Between Momentum Investing and Long Term Investing
- Broadcom Gets Second $420 Target as CPO Win Boosts Outlook
- Overbought Stocks Explained: Should You Trade Them?
- PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.